In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Lokavant provides clinical trial intelligence
Free Treatment, investigations and sex change surgery along with other facilities will be available at these OPDs for the Transgender community
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Subscribe To Our Newsletter & Stay Updated
